共 112 条
[1]
Blasius H(2014)Arzneimittelzulassung: Teil 2: Europäisches Zulassungssystem, Änderungen an Arzneimitteln nach der Zulassung Dtsch Apoth Z 38 82-1304
[2]
Borell S(2015)Spinale Muskelatrophie Monatsschr Kinderheilkd 163 1293-980
[3]
Pechmann A(2017)Ethics review in compassionate use BMC Med 15 136-767
[4]
Kirschner J(2016)The ethical challenges of compassionate use JAMA 315 979-1387
[5]
Borysowski J(2018)Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials J Med Ethics 44 761-1732
[6]
Ehni HJ(2017)Regulatory review of new therapeutic agents – FDA versus EMA, 2011–2015 N Engl J Med 376 1386-1459
[7]
Górski A(2020)Health ministers condemn Novartis lottery for Zolgensma, the world’s most expensive drug BMJ 368 m580-161
[8]
Caplan AL(2020)Fair allocation of scarce medical resources in the time of Covid-19 N Engl J Med 377 1723-363
[9]
Ray A(2017)Nusinersen versus sham control in Infantile-Onset Spinal Muscular Atrophy N Engl J Med 33 1453-997
[10]
Caplan AL(2014)Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals Health Aff 20 155-431